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Venlafaxine treatment reduces 
the deficit of executive control of 
attention in patients with major 
depressive disorder
Yanghua Tian1,*, Jing Du2,*, Alfredo Spagna3,*, Melissa-Ann Mackie3,*, Xiaosi Gu4, Yi Dong5, 
Jin Fan3,6,7 & Kai Wang1
Attention plays an essential role in supporting other cognitive functions and behavior, and disturbance 
of attention is one of the most common symptoms in major depressive disorder (MDD). Although 
treatment with venlafaxine for MDD symptoms has been shown to reduce deficits in cognition and 
emotion regulation, it remains unclear whether venlafaxine improves specific attentional functions. 
We used the Attention Network Test to measure the attentional functions of alerting, orienting, 
and executive control before and after treatment with venlafaxine in patients with MDD compared 
to untreated healthy controls. Before treatment, the MDD group showed a selective impairment in 
alerting and executive control of attention, while there were no significant group differences in the 
orienting function. The interaction between group and session was significant for executive control, and 
after treatment with venlafaxine, the performance of the MDD group on executive control of attention 
was not significantly different from that of controls. Reported symptoms of MDD were also significantly 
reduced after treatment with venlafaxine. These results demonstrate that treatment with venlafaxine 
selectively normalizes the executive control function of attention in addition to improving clinical 
symptoms in MDD.
Major depressive disorder (MDD) is the most common type of psychiatric disorder, with lifetime prevalence 
estimates of more than 3.5% in China1. In addition to mood symptoms, it is often associated with deficits in atten-
tion2–4, executive functions4–6, and processing speed5,7. These are considered to be primary features of the disorder 
and have a negative impact on functional and social ability8–10. Attention plays an essential role in supporting 
other cognitive functions and behavior, and its disturbance is one of the most common symptoms in MDD, with 
frequent complaints of difficulty maintaining concentration10. A wealth of studies have provided empirical evi-
dence for these attention deficits, such as in the alerting2,3,11 and orienting11 functions of attention, although some 
controversy still exists4,11. However, whether current pharmacological interventions are effective in the treatment 
of these deficits is unclear. Hence, a comprehensive assessment of treatment outcomes should investigate the 
change in cognitive functions, such as attention, together with changes in the clinical symptoms.
Attention can be conceptualized as three separable functions of alerting, orienting, and executive control, 
supported by corresponding brain networks and neurotransmitter systems12,13. Alerting contributes to the main-
tenance of readiness and has been associated with activation in the thalamus, and frontal and parietal cortical 
regions14, and with the cortical distribution of the norepinephrine (NE) neurotransmitter system15. Orienting 
is responsible for selecting and moving attention to stimuli, and is supported by frontal and parietal regions 
and the acetylcholine (Ach) neurotransmitter system16,17. Executive control is involved in resolving conflicts 
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and coordinating among thoughts and actions18,19, and often activates areas in the frontoparietal network (FPN) 
including the anterior cingulate cortex (ACC) and other frontoparietal regions14,20, and is modulated by the 
mesocortical dopamine (DA) system21. The efficiency of these attentional functions can be measured using the 
Attention Network Test (ANT)13. Using this paradigm, selective and multiple attentional function impairments 
have been found to be associated with different psychiatric disorders22,23. Although previous studies have exam-
ined specific attentional function deficits in MDD using other tasks2–4,24, the selective impairment of attention in 
MDD and treatment effects on attention are still unclear.
Deficits in attentional systems may be linked to dysfunction in specific neurotransmitter systems that have 
been associated with MDD. Specifically, dysfunctions in serotonin (5-HT), NE, and DA systems have been con-
sistently associated with MDD25 and current antidepressant treatments act on these neurotransmitters to reduce 
the clinical symptoms. Venlafaxine is an antidepressant in a group of drugs called serotonin-norepinephrine 
reuptake inhibitors (SNRI), and is recognized as a safe, rapidly effective, and widely used antidepressant26,27. 
Its main mechanism of action is the inhibition of 5-HT reuptake, with dose-dependent inhibition of NE reup-
take28, and weak DA reuptake inhibition29. Furthermore, there is evidence that venlafaxine might also increase 
dopamine levels in striatum, hippocampus, and frontal brain regions28,30–32. Given that venlafaxine acts on neu-
rotransmitters systems relevant to attention, and the persistence of attentional deficits in patients with MDD33, it 
is important to clarify whether treatment with this antidepressant also treats deficits in the attentional functions.
The present study examined the effects of treatment with venlafaxine on the attentional deficits associated 
with MDD. Because NE and DA are implicated in the neurobiology of MDD, we hypothesized that patients with 
MDD would show impairment in the alerting and executive control functions. Importantly, because venlafaxine 
acts upon these neurotransmitters, we also hypothesized that the treatment with venlafaxine would reduce these 
attentional deficits.
Results
Clinical symptoms and treatment effects. There were no significant differences between the MDD and 
HC groups in age, education, or MMSE scores (see Table 1). In the MDD group, the 24-item Hamilton Rating 
Scale for Depression (HRSD)34 scores decreased significantly from the pre-test (37.5 ± 5.8) to post-test session 
(4.5 ± 5.6), (t(33) = 25.4, p < 0.001). The Self-Rating Depression Scale (SDS)35 scores also decreased significantly 
from pre-test (51.8 ± 9.4) to post-test (29.3 ± 5.6), (t(33) = 12.1, p < 0.001). See Fig. 1 for the treatment effects of 
clinical symptoms.
Overall reaction time and error rate. Table 2 and Fig. 2 show the overall reaction time (RT) and error 
rate (ER) group differences. Trials with 3 standard deviations (SD) above the mean RT were considered outliers 
and excluded from further analysis. For the overall RT, the main effect of Group was significant (F(1,62) = 15.4, 
p < 0.001) indicating that the MDD group (683 ± 120 ms) responded significantly slower than the HC group 
(584 ± 84 ms). The main effect of Session was significant (F(1,62) = 32, p < 0.001) indicating that RT was reduced 
from pre-test (661 ± 136 ms) to post-test (611 ± 95 ms). The Group by Session interaction was significant 
(F(1,62) = 10.7, p < 0.05). Simple comparisons revealed that in the MDD group, RT decreased significantly from 
pre-test (721 ± 141 ms) to post-test session (644 ± 100 ms) (F(1,62) = 42.7, p < 0.01), while the difference in RT 
between the two sessions (594 ± 91 ms and 573 ± 73 ms, respectively) in the HC group was not significant 
(F(1,62) = 2.7, p = 0.10).
For the overall ER, the main effect of Group was significant (F(1,62) = 4.1, p < 0.05), indicating that the HC 
group (3.1 ± 2.9%) made more errors than the MDD group (1.9 ± 2.3%). The main effect of Session was not sig-
nificant (F(1,62) = 3.5, p = 0.07). The Group by Session interaction was significant (F(1,62) = 6.4, p < 0.05). Simple 
comparisons revealed that the ER was significantly reduced from the pre-test session (2.6 ± 3.1%) to the post-test 
session (1.2 ± 1.3%) (F(1,62) = 10.3, p < 0.01) in the MDD group, while the difference in the ER between the two 
sessions (3.0 ± 2.8% and 3.2 ± 3.1%, respectively) in the HC group was not significant (F < 1).
Attentional deficits and treatment effects. Table 2 and Fig. 3 show the attentional effects for both 
groups within the two sessions.
The alerting effect. For RT, the main effect of Group was significant (F(1,62) = 12.3, p < 0.05), indicating a smaller 
alerting effect in the MDD group (27 ± 30 ms) compared to the HC group (39 ± 23 ms). The main effect of Session 
was not significant (F(1,62) = 1.7, p = 0.19 ). The Group by Session interaction was not significant (F(1,62) = 1.8, 
p = 0.19). For ER, the main effects of Group (F(1,62) = 1.4, p = 0.24), and Session (F < 1), and the Group by Session 
interaction (F < 1) were not significant.
MDD (n = 34) HC (n = 30) Test p 
Sex (Female/Male) 24/10 19/11 χ2 = 0.38 0.54
Age in years 36.1 ± 13.3 34.2 ± 12.2 t = 0.58 0.56
Education in years 10.6 ± 3.9 10.8 ± 3.8 t = 0.29 0.78
MMSE 29.3 ± 1.2 29.5 ± 0.8 t = 0.68 0.45
Table 1.  Demographic data of patients with MDD and healthy controls (Mean ± SD). Note: MMSE = Mini-
mental state examination.
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The orienting effect. For RT, the main effects of Group and Session (Fs < 1) and the Group by Session inter-
action effect (F(1,62) = 1.1, p = 0.29) were not significant. For ER, the main effects of Group (F < 1) and Session 
(F(1,62) = 2.0, p = 0.15 ), and the Group by Session interaction (F < 1) were not significant.
The executive control effect. For the RT, the main effect of Group was not significant (F(1,62) = 3.1, p = 0.09). 
The main effect of Session was significant (F(1,62) = 13.2, p < 0.01), indicating a greater conflict effect in the 
pre-test (98 ± 38 ms) compared to post-test (post 85 ± 37 ms). The Group by Session interaction was signif-
icant (F(1,62) = 4.9, p < 0.05). Simple comparisons indicated that the executive control effect was significantly 
reduced from pre-test session (109 ± 43 ms) to post-test session (88 ± 41 ms) in the MDD group (F(1,62) = 18.3, 
p < 0.01), while the difference in the conflict effect between the two sessions was not significant for the HC group 
(F < 1). The post-test difference in the conflict effect between the HC and the MDD groups was not signifi-
cant (F(1,62) = .84; p = .36). Bayesian t test for accepting or rejecting the null hypothesis (http://pcl.missouri.edu/
bf-two-sample) favored the null. For ER, the main effects of Group (F < 1), Session (F < 1), and the Group by 
Session interaction (F < 1) were not significant.
Correlations between attentional functions and clinical scores. There were no significant correlations between 
attentional functions and symptom scores of the HRSD and SDS neither at pre-test, nor between the attentional 
effect change and symptom change scores at post-test.
Discussion
This study demonstrated slower overall response speed in the MDD group, as well as pre-treatment attentional 
deficits in the alerting and executive control functions of attention. This result is consistent with other studies 
showing that depression is associated with deficits in executive control4–6,36. The executive control of attention has 
been extensively related to the activity of several frontal and parietal areas (FPN37), and in particular to the acti-
vation of the ACC, which depends on the mesocortical DA system38–40. Hypofunction and abnormal structure in 
ACC have been shown to be associated with major depression41,42. Therefore, the impairment of executive control 
function in MDD may be caused by dysfunction of this region within the FPN.
Furthermore, venlafaxine treatment selectively improved the executive control component of attention. This 
observed selective treatment effect may be due to direct and indirect effects of this medication on the DA system 
which improved the efficiency of this function within the patient group. Previous studies have demonstrated 
that venlafaxine increases DA level in frontal lobe and limbic system30–32. Furthermore, there is abundant phys-
iological evidence for complex modulation and interactions between 5-HT and DA systems within the frontal 
lobes. 5-HT has been shown to have an inhibitory effect on DA neurotransmission43,44, and a reduction in avail-
able 5-HT, as implicated in the neurobiology of MDD, may result in release from inhibition of the DA system, 
Figure 1. Clinical symptom scores at pre- and post-test in MDD patients treated with venlafaxine. Note: 
**p < 0.01.
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resulting in impulsivity, a hallmark of deficient executive control. Consequently, increasing the availability of 
5-HT within frontal cortex via SNRI treatment may account for improvement of the executive control of atten-
tion45,46. However, further investigations that directly compare drugs designed to target different neurotransmit-
ter systems are needed in order to draw strong conclusions about the specificity of these mechanisms.
The improvement of executive control of attention is not trivial. A previous study demonstrated that this atten-
tional function contributes significantly to the implementation of cognitive control, which is necessary for execut-
ing high-level cognitive functions47. The efficiency of cognitive control and executive functions is directly related 
to functional outcomes in MDD48,49. Furthermore, cognitive control is involved in emotion regulation50 and the 
suppression of dysfunctional thoughts51, which are common in MDD. Consequently, treatment of this attention 
component may result in improvement in cognitive control, emotion regulation, and in overall daily functioning.
Based on the deficient NE neurotransmission associated with MDD, we also predicted that the patient group 
would show a deficit of the alerting function (which is related to the NE system52), and that this deficit would be 
reduced by venlafaxine. The reduced alerting effect observed in the patient group suggests a lower level of read-
iness to respond to external stimuli2. However, we did not find evidence of a treatment effect with venlafaxine 
on the alerting deficit. It has been noted that the inhibition of reuptake of NE typically occurs at dosage greater 
than 150 mg/day28,53; 150 mg/day was the maximum dose used in this study and therefore may not have been high 
enough to directly act on the NE system. Given that typical maximum clinical doses can be as high as 375 mg per 
day, and previous evidence indicating that significant effects on the noradrenergic system are achieved only with 
high doses of venlafaxine54, it is possible that higher dosages than were used in this study might have a treatment 
effect on the alerting function, though higher doses tend to increase the likelihood of adverse side effects55.
The prediction that there would be no deficit in the orienting of attention associated with MDD, as shown in 
previous studies2,4, was confirmed also by our results. Furthermore, venlafaxine does not act on the cholinergic 
system28, and we did not expect any change in the orienting function due to the treatment. Previous studies have 
demonstrated that both the depletion of 5-HT and NE-blocking drugs, the two mechanisms by which venlafaxine 
exerts its effect, have no influence on the orienting performance56,57.
Figure 2. Overall reaction time and error rate for MDD and HC groups in the pre- and post-test sessions. 
Patients with MDD showed a significantly slower responding speed than controls in pre-test session. After 
treatment with venlafaxine, there was a significant improvement in response time in the MDD group. Note: * * 
p < 0.01.
MDD (n = 34) HC (n = 30)
Pre-test Post-test Pre-test Post-test
Reaction Time
 Overall 721 (141) 644 (100) 594 (91) 573 (75)
 Alerting 25 (28) 29 (32) 36 (23) 42 (23)
 Orienting 54 (38) 54 (23) 59 (21) 51 (21)
 Executive control 109 (43) 88 (41) 86 (31) 81 (32)
Error Rate
 Overall 2.6 (3.3) 1.2 (1.3) 3.0 (2.8) 3.2 (3.1)
 Alerting 0.2 (3.5) 0.2 (2.4) − 0.5 (3.5) − 0.6 (2.8)
 Orienting 0.9 (3.7) 0.1 (1.6) 0.7 (3.2) − 0.02 (2.5)
 Executive control 2.8 (5.6) 1.8 (2.2) 1.7 (2.9) 1.6 (2.2)
Table 2.  Attention network scores for Reaction Time (SD), in ms, and Error Rate (SD), in percent, of MDD 
and HC groups.
www.nature.com/scientificreports/
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Although cognitive impairments are nowadays often associated with major depression5, the relationship 
between attentional deficits and clinical symptoms of MDD is still under debate. For example, there is some 
evidence showing that the cognitive deficits and clinical symptoms may be due to abnormalities of cortical and 
subcortical regions, however, the cognitive impairment seems to be more durable than the clinical symptoms58. 
In the current study, although the treatment with venlafaxine reduced the deficit in the executive control func-
tion together with effectively reducing the clinical symptomatology, the changes in the two measures were not 
correlated, which may suggest that the attentional deficits and symptom severity may arise from independent 
mechanisms.
There are some limitations to this study that may restrict the strength of the conclusions. The sample size in 
this study was relatively limited, and a larger study would allow for stronger conclusions about the attentional 
deficits and treatment effects. Furthermore, because all patients received treatment with venlafaxine only, we were 
not able to compare the effects of different types of antidepressants on attentional functions. Such a comparison 
could help to further clarify the role of intervening at the level of neurotransmission to improve the cognitive and 
clinical symptoms of MDD. Future studies may also aim to increase the treatment duration (longer than the six 
weeks in this study) to determine the optimal treatment length for maximum gain in attentional improvement.
In conclusion, we found that there were deficits in the alerting and executive control of attention in MDD, and 
showed that venlafaxine selectively improved the executive control of attention. There was no evidence for deficits 
in the orienting function. Antidepressants that improve cognitive function in addition to clinical symptoms have 
great potential to reduce the functional impairment associated with MDD.
Methods
Participants. Fifty-three patients with MDD were recruited from Anhui Mental Health Center affiliated with 
Anhui Medical University, China. Diagnosis of MDD was by consensus of two independent psychiatrists using 
the Structured Clinical and Interview for DSM-IV. MDD participants were drug naïve or drug free for at least 
3 months prior to the study, and only patients eligible for venlafaxine treatment were recruited and were moni-
tored for dose titration and adverse side effects. The 24-item HRSD and SDS were used to measure the severity of 
Figure 3. The attentional effects for the MDD group and for to the HC group in the pre- and post-test 
sessions. In the pre-test session, the MDD group showed a selective impairment in alerting and executive 
control of attention in reaction time. In the post-test session, the performance of the MDD group on executive 
control of attention was not significantly different from that of HC in reaction time. Note: * p < 0.05.
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clinical symptoms. The Mini-Mental State Examination (MMSE)59 was administered to all participants and only 
those who scored higher than 27 were included in order to exclude mild cognitive impairment and dementia. 
Patients with a history of brain tumor, stroke, or other neurological disease that could interrupt brain function 
were excluded. Four patients showing intolerance to the treatment with venlafaxine were excluded from this study 
and received an alternative antidepressant treatment. In total, 19 patients discontinued their participation in this 
study. The final MDD sample consisted of thirty-four patients (10 males and 24 females; mean age = 36 ± 13 
years; average years of education = 11 ± 4 years).
Thirty healthy controls (HC; 11 males and 19 female) were recruited (mean age = 34 ± 12.2 years; average 
years of education = 11 ± 4 years). HC participants were evaluated by staff psychiatrists, and individuals with 
history of neurological, psychiatric, or systemic medical disorders were not included. All participants had nor-
mal or corrected to normal vision and gave written informed consent. The ethical committee of Anhui Medical 
University approved this study, and methods and procedures of this study were in accordance with the approved 
guidelines.
Attention Network Test. Figure 4 illustrates the stimuli and sequence of events in the ANT. Stimuli con-
sisted of a row of five visually presented horizontal black lines, with arrowheads pointing leftward or rightward, 
against a gray background. The target was a left- or right-pointing arrowhead in the center, flanked on either side 
by two arrows pointing in the same direction (congruent condition), or in the opposite direction (incongruent 
condition), or by horizontal lines (neutral condition). A single arrow or line extended 0.55° of the visual angle 
and the contours of adjacent arrows or lines were separated by 0.06° of the visual angle. The row of five stimuli 
was presented at 1.06° either above or below the central fixation cross. Participants were asked to identify the 
direction of the central arrow by pressing one computer mouse button for the left direction and a second button 
for the right direction. Cues consisted of a 100 ms asterisk presented 400 ms before the target. There were four 
cue conditions: (1) no-cue, in which the central fixation cross remained present and unchanged; (2) central-cue, 
which appeared at the central fixation point; (3) double-cue, in which cues were presented on the two possible tar-
get locations simultaneously; and (4) spatial-cue, in which the cue was presented at the location of the upcoming 
target. The task consisted of a 24-trial practice block and three experimental blocks of trials. Each experimental 
block consisted of 96 trials (48 conditions: 4 warning levels × 2 target locations × 2 target directions × 3 congru-
ency conditions, with 2 repetitions). The presentation of trials was randomized. Participants were instructed to 
fixate at a centrally located cross throughout the task, and to respond as quickly and accurately as possible.
Effects for each attentional function were calculated based on the RT and ER data. The alerting effect was 
calculated by subtracting the mean RT of the double cue condition from the mean RT of the no cue condition. 
The orienting effect was calculated by subtracting the mean RT of the spatial cue condition from the mean RT 
of the center cue condition. For the ER computations of alerting and orienting, the subtractions were reversed 
to yield positive effect scores. The executive control effect was calculated by subtracting the mean RT (or ER) of 
congruent conditions from the mean RT (or ER) of incongruent conditions. The calculations of attentional effects 
are described in detail in a previous publication13.
Procedure. In the pre-test session, participants from both groups completed the MMSE, and the ANT. The 
MDD group also completed the HRSD and SDS. MDD patients were then treated with venlafaxine with a starting 
dose of 75 mg, gradually increased up to 75–150 mg daily. At the 6-week time point (post-test session) the MDD 
group then completed the ANT, HRSD and SDS again. During the six-week period, patients did not receive any 
other treatment. The untreated HC group was also post-tested on the ANT after a 6-week interval.
Figure 4. Experimental procedure: (a) the four cue conditions; (b) the three target conditions (six target types) 
used in the present experiment; and (c) an example of the procedure. In this task, participants made responses 
to indicate the direction of a central arrow (left or right).
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Data Analysis. Mixed factorial analyses of variance with Group (HC, MDD) as the between-subjects factor 
and Session (pre-test, post-test) as the within-subjects factor were performed on each attentional effect in both 
RT and ER. Simple comparisons were used to further analyze significant interaction effects. Spearman correla-
tion analyses were conducted between attentional effects and pre-test clinical symptoms, and between changes 
(pre-test minus post-test) in the attentional effects and changes in the clinical symptoms after venlafaxine treat-
ment, and a corrected critical α value of p < 0.01 was used.
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